NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
Trump Tariffs Show Minimal Economic Impact but Boost Federal Revenue, Study Finds 
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market 
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence 
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling 
Japan's Private Sector Growth Slows in March Amid Rising Costs and Middle East Uncertainty 
Gold Prices Surge on U.S.-Iran Ceasefire Reports 
Australia-EU Free Trade Deal Signed After Years of Negotiations 
Asian Markets Rally as Oil Prices Tumble and Middle East Peace Hopes Emerge 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
Asian Currencies Stay Muted as Dollar Holds Firm Amid Iran Uncertainty 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Gold is meant to be a ‘safe haven’ in uncertain times. Why is it crashing amid a war? 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Middle East War Rattles Global Markets as Oil Tops $100 and Dollar Surges 
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Pfizer inc., an American pharmaceutical and biotechnology firm headquartered in Manhattan, New York City, has agreed to buy Global Blood Therapeutics biotech company for $5.4 billion. The drugmaker will be paying $68.50 a share for the acquisition.
According to Reuters, Pfizer will purchase the blood disorder medicine producer as it would like to bolster its drug lineup to counter or fight a possible slowdown in the demand for COVID medicines and other products since the cases are starting to fall.
Pfizer was one of the drugmakers that earned the most at the height of the COVID-19 pandemic since it supplied the vaccines around the world. With most people worldwide now fully vaccinated, the company is now looking for acquisitions that will bring in profits annually
Pfizer confirmed on Monday, Aug. 8, that it will be paying $68.50 per share to buy Global Blood Therapeutics. This amount is equivalent to a premium of around 7.3% to the stock's closing price last Friday.
Following the announcement of the deal with Pfizer, the shares of Global Blood reportedly soared by 4.5%. The company is known for its blood disorder drug called Oxbryta, which was first approved in 2019.
It is used for the treatment of sickle cell disease in patients who are 12 years old or older. In December 2021, it was also approved for the treatment of younger patients who are suffering from the said disease.
“Sickle cell disease is the most common inherited blood disorder, and it disproportionately affects people of African descent. We are excited to welcome GBT colleagues into Pfizer and to work together to transform the lives of patients, as we have long sought to address the needs of this underserved community,” Pfizer’s chairman and chief executive officer, Albert Bourla, said in a press release.
He added, “The deep market knowledge and scientific and clinical capabilities we have built over three decades in rare hematology will enable us to accelerate innovation for the sickle cell disease community and bring these treatments to patients as quickly as possible.”
